Fenebrutinib in PPMS: Insights from ACTRIMS Forum 2026
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Fenebrutinib in PPMS: Insights from ACTRIMS Forum 2026
-
Narrated by:
-
By:
About this listen
Clinical trial results unveiled today at ACTRIMS Forum 2026 suggest that fenebrutinib may be a novel and effective treatment option for people living with primary progressive multiple sclerosis. In this exclusive episode providing the first expert discussion of the complete dataset, FENtrepid trial leads Prof. Amit Bar-Or (University of Pennsylvania) and Dr. Stephen Hauser (University of California San Francisco) break down what the fenebrutinib results really show. Together, they explore:
- Why BTK inhibition is uniquely positioned to address progressive MS biology
- How fenebrutinib compared to ocrelizumab in the Phase 3 FENtrepid PPMS trial
- What the data suggest for patients with non-relapsing, chronic disease
Listen for a deep dive into the science and the clinical implications.
Editorial Note:
At 21:49, the discussion refers to Müller cells. The correct term is Kupffer cells.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.